<DOC>
	<DOCNO>NCT01453855</DOCNO>
	<brief_summary>The purpose study demonstrate intraocular pressure-lowering efficacy Travoprost 0.003 % equivalent TRAVATANÂ® adult patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Travoprost 3-Month Safety Efficacy Study</brief_title>
	<detailed_description>This study consist six visit conduct two sequential phase . The Screening/Eligibility phase include one screen visit two eligibility visit . A washout period base previous ocular medication precede Eligibility Visit 1 . Subjects meet inclusion/exclusion criterion eligibility visit randomize ( 1:1 ) second eligibility visit . The Treatment phase consist three on-therapy visit ( Week 2 , Week 6 , Month 3 ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis openangle glaucoma ( include openangle glaucoma pseudoexfoliation pigment dispersion ) ocular hypertension . Qualifying intraocular pressure eligibility visit . Understand sign inform consent form . Other protocoldefined inclusion criterion may apply . Women childbearing potential pregnant , breastfeeding , adequate birth control . Severe central visual field loss either eye . Chronic , recurrent severe inflammatory eye disease . Best correct visual acuity ( BCVA ) score bad 55 ETDRS letter ( equivalent 20/80 Snellen ) . Any abnormality prevent reliable applanation tonometry . Hypersensitivity prostaglandin analog component study medication . Therapy another investigational agent within 30 day prior Screening Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>